新冠肺炎患者的嗅觉和味觉障碍

Q3 Medicine

Allergo Journal International Pub Date : 2022-06-20 DOI:10.1007/s40629-022-00216-7

Ludger Klimek, Jan Hagemann, Julia Döge, Laura Freudelsperger, Mandy Cuevas, Felix Klimek, Thomas Hummel

{"title":"新冠肺炎患者的嗅觉和味觉障碍","authors":"Ludger Klimek, Jan Hagemann, Julia Döge, Laura Freudelsperger, Mandy Cuevas, Felix Klimek, Thomas Hummel","doi":"10.1007/s40629-022-00216-7","DOIUrl":null,"url":null,"abstract":"<div><h2>Summary</h2><div><p>Loss of olfaction is one of the symptoms most commonly reported by patients with coronavirus disease 2019 (COVID-19). Although the spontaneous recovery rate is high, recent studies have shown that up to 7% of patients remain anosmic for more than 12 months after the onset of infection, leaving millions of people worldwide suffering from severe olfactory impairment. Olfactory training remains the first recommended treatment. With the continued lack of approved drug treatments, new therapeutic options are being explored. This article reviews the current state of science on COVID-19-related olfactory disorders, focusing on epidemiology, pathophysiology, cure rates, currently available treatment options, and research on new treatments.</p></div></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"31 7","pages":"243 - 250"},"PeriodicalIF":0.0000,"publicationDate":"2022-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00216-7.pdf","citationCount":"13","resultStr":"{\"title\":\"Olfactory and gustatory disorders in COVID-19\",\"authors\":\"Ludger Klimek, Jan Hagemann, Julia Döge, Laura Freudelsperger, Mandy Cuevas, Felix Klimek, Thomas Hummel\",\"doi\":\"10.1007/s40629-022-00216-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h2>Summary</h2><div><p>Loss of olfaction is one of the symptoms most commonly reported by patients with coronavirus disease 2019 (COVID-19). Although the spontaneous recovery rate is high, recent studies have shown that up to 7% of patients remain anosmic for more than 12 months after the onset of infection, leaving millions of people worldwide suffering from severe olfactory impairment. Olfactory training remains the first recommended treatment. With the continued lack of approved drug treatments, new therapeutic options are being explored. This article reviews the current state of science on COVID-19-related olfactory disorders, focusing on epidemiology, pathophysiology, cure rates, currently available treatment options, and research on new treatments.</p></div></div>\",\"PeriodicalId\":37457,\"journal\":{\"name\":\"Allergo Journal International\",\"volume\":\"31 7\",\"pages\":\"243 - 250\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s40629-022-00216-7.pdf\",\"citationCount\":\"13\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergo Journal International\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s40629-022-00216-7\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergo Journal International","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1007/s40629-022-00216-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 13

摘要

摘要嗅觉丧失是2019冠状病毒病（新冠肺炎）患者最常见的症状之一。尽管自发恢复率很高，但最近的研究表明，高达7%的患者在感染后12个月以上仍有嗅觉缺失，导致全球数百万人患有严重的嗅觉障碍。嗅觉训练仍是首选治疗方法。由于持续缺乏批准的药物治疗，正在探索新的治疗方案。本文综述了COVID-19相关嗅觉障碍的科学现状，重点介绍了流行病学、病理生理学、治愈率、目前可用的治疗方案以及新治疗方法的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Olfactory and gustatory disorders in COVID-19

Summary

Loss of olfaction is one of the symptoms most commonly reported by patients with coronavirus disease 2019 (COVID-19). Although the spontaneous recovery rate is high, recent studies have shown that up to 7% of patients remain anosmic for more than 12 months after the onset of infection, leaving millions of people worldwide suffering from severe olfactory impairment. Olfactory training remains the first recommended treatment. With the continued lack of approved drug treatments, new therapeutic options are being explored. This article reviews the current state of science on COVID-19-related olfactory disorders, focusing on epidemiology, pathophysiology, cure rates, currently available treatment options, and research on new treatments.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Allergo Journal International Medicine-Immunology and Allergy

CiteScore

4.60

自引率

0.00%

发文量

期刊介绍： Allergo Journal International is the official Journal of the German Society for Applied Allergology (AeDA) and the Austrian Society for Allergology and Immunology (ÖGAI). The journal is a forum for the communication and exchange of ideas concerning the various aspects of allergy (including related fields such as clinical immunology and environmental medicine) and promotes German allergy research in an international context. The aim of Allergo Journal International is to provide state of the art information for all medical and scientific disciplines that deal with allergic, immunological and environmental diseases. Allergo Journal International publishes original articles, reviews, short communications, case reports, and letters to the editor. The articles cover topics such as allergic, immunological and environmental diseases, the latest developments in diagnosis and therapy as well as current research work concerning antigens and allergens and aspects related to occupational and environmental medicine. In addition, it publishes clinical guidelines and position papers approved by expert panels of the German, Austrian and Swiss Allergy Societies. All submissions are reviewed in single-blind fashion by at least two reviewers. Originally, the journal started as a German journal called Allergo Journal back in 1992. Throughout the years, English articles amounted to a considerable portion in Allergo Journal. This was one of the reasons to extract the scientific content and publish it in a separate journal. Hence, Allergo Journal International was born and now is the international continuation of the original German journal. Nowadays, all original content is published in Allergo Journal International first. Later, selected manuscripts will be translated and published in German and included in Allergo Journal.